The therapeutic efficacy of existing PD-1 and/or CTLA4 inhibitors was not different between the two groups; however, numerous emerging clinical trials evaluating ICIs in HCC are underway (e.g., targeting TIGIT, CD80, and LAG-3) [67], painting a brighter prospect for the treatment of patients in high-risk groups. This evidence concerns the gene LAG3 and hepatocellular carcinoma.